MDMA-assisted therapy for PTSD: what the trials actually show

MDMA — the pharmaceutical form is called midomafetamine — is not given as a daily pill. In the trials it was used as a catalyst inside a structured course of psychotherapy, and the distinction is not a technicality: it changes what is being tested and what a patient would be signing up for.^[1]

The protocol looked like this. Roughly three preparatory therapy sessions built rapport and set expectations. Then came three day-long dosing sessions of about eight hours each, with a pair of co-therapists present throughout, using doses in the region of 80–180 mg with an optional supplemental dose. Each dosing day was followed by several integration sessions to make sense of what surfaced. The whole course ran about twelve weeks.^[2]

The point worth holding onto: the drug and the therapy are inseparable here. This is a treatment package, not a medication — and that fact shapes both the results and the regulatory questions that followed.

MDMA triggers the release of serotonin and, to a lesser degree, norepinephrine and dopamine, along with downstream release of oxytocin and prolactin. That neurochemical profile is unusual: it is stimulating and empathogenic at once.^[3]

Neurobiologically, the most relevant effect is on the amygdala, the brain's threat detector. MDMA reduces its reactivity to fearful stimuli and appears to strengthen fear-extinction learning. The working model is that it opens a window in which traumatic memories can be revisited and reconsolidated with less overwhelming fear, while the increase in feelings of trust and safety lets a patient stay engaged with painful material rather than shutting down or dissociating away from it.^[3]

This is precisely why the drug is paired with therapy rather than used alone. The pharmacology does not treat PTSD; it is proposed to make the psychological work possible for people in whom that work has otherwise been intolerable.

The first phase 3 trial randomized 90 people with severe, chronic PTSD — many of whom had lived with the condition for well over a decade — to MDMA-assisted therapy or to the same therapy with placebo.^[1]

On the primary outcome, the CAPS-5 total severity score (higher is worse), the MDMA group fell 24.4 points versus 13.9 for placebo-with-therapy. That is a between-group difference of 11.9 points (95% CI 6.3–17.4), a large effect size (Cohen's d = 0.91), p < 0.0001.^[1]

In clinical terms: 67% of the MDMA group no longer met diagnostic criteria for PTSD, versus 32% on placebo, and 33% reached remission versus 5%. On safety, there were no serious adverse events in the MDMA arm; the two serious suicidality events in the study occurred in the placebo group.^[1]

The confirmatory trial randomized 104 people with moderate-to-severe PTSD and deliberately enrolled a more diverse population than its predecessor: about one-third identified as other than White, and roughly 27% as Hispanic/Latino. Mean PTSD duration was around sixteen years, with high rates of comorbidity.^[2]

On the primary outcome, CAPS-5 fell 23.7 points on MDMA versus 14.8 on placebo-with-therapy (p < 0.001), with an effect size of Cohen's d = 0.7 — smaller than MAPP1 but still large by psychiatric standards.^[2]

71.2% of the MDMA group no longer met PTSD criteria versus 47.6% on placebo, and 46.2% reached remission versus 21.4%. Functional impairment, measured with the Sheehan Disability Scale, also improved significantly more on MDMA — an important detail, because symptom scores and the ability to work and relate to people do not always move together.^[2]

Severe treatment-emergent adverse events occurred in 5 of 53 (9.4%) on MDMA versus 2 of 51 (3.9%) on placebo. There were no deaths, and no reports of MDMA abuse or dependence.^[2]

In June 2024, an FDA advisory committee voted overwhelmingly against the application. Just 2 of 11 members agreed the data showed the treatment was effective, and only 1 of 11 agreed its benefits outweighed its risks.^[6]

In August 2024 the FDA issued a Complete Response Letter declining approval and asking for an additional phase 3 study; the letter was later made public in 2025.^[4][5]

The concerns, in plain terms, were four. First, functional unblinding: because MDMA is powerfully psychoactive, most participants and therapists could tell who had received the drug, which can inflate reported benefit through expectancy bias. Second, the durability of benefit and incomplete long-term data. Third, safety data seen as insufficient to fully characterize cardiovascular effects, potential liver effects and abuse potential. Fourth, trial-conduct and oversight problems, including how hard the psychotherapy component is to standardize and reports of misconduct at an earlier-phase site.^[4][5][6]

Both things can be held at once. The effect sizes are large and consistent across two independent phase 3 trials in a condition that is notoriously hard to treat — that is a real signal, not noise. Two-thirds to three-quarters of participants no longer meeting diagnostic criteria is a striking result in a population with a mean illness duration measured in decades.^[2]

But the criticisms are substantive, not merely bureaucratic. Blinding is a genuine scientific problem for any strongly psychoactive compound, and functional unblinding can bias both patient-reported and clinician-rated outcomes in the same direction. Sample sizes were modest. The therapy component is difficult to standardize and therefore difficult to evaluate or reproduce at scale. And real-world safety — cardiovascular load, misuse, what happens outside a tightly controlled setting with two therapists in the room — needs more data than two trials can supply.^[4]

The honest reading is that both the promise and the caution are real. Anyone selling you only one half of that sentence is simplifying.

As of 2026, MDMA-assisted therapy is investigational. It is not approved and not legally available in the United States or Canada outside an authorized clinical trial.^[2]

Lykos Therapeutics, formerly MAPS PBC, has accepted the FDA's position that reviving the application requires a fresh phase 3 trial, alongside possible independent re-analysis of the earlier data. The episode has reset expectations across the psychedelic field and prompted redesigned trials with better blinding, more standardized therapy and cleaner safety capture.^[5]

For someone living with PTSD today, evidence-based options already exist — trauma-focused psychotherapies and, where appropriate, medication — and other approaches are under active study, including our review of ketamine for depression. Because sleep disruption is both a symptom and a driver of trauma-related illness, Peak Human's guide to sleep optimization is worth reading alongside any treatment plan.